The company said it did not rule out the possibility of seeking independent financing and being listed in the future, but added there were no detailed plans at present.
The company is beefing up efforts in the recycling and reutilizing of used lead-acid batteries. China produces 3.3 million metric tons of scrap lead-acid batteries every year, a major source of pollution if not handled well, but a lucrative market if it was treated properly, Zhang explained.
The company noted that the number of tourists visiting Southeast Asian countries and regions related to the initiative in the past three years has grown between 10 and 15 percent annually.
The company hasn’t yet announced the new offering?and didn’t respond to questions about how it will work. But signs?inside the company’s new Kirkland, Wash., facility indicate Amazon Flex?will be a?new way for the company to distribute?packages, possibly letting customers pick up items from the Prime Now?center themselves.
The company's main strategy in 2018 is to improve its twin growth drivers-its search engine and input method-with the help of artificial intelligence technology, Wang said.
The company said net revenue for the third quarter of 2019 rose 10 percent year-on-year to 19.6 billion yuan, compared with 17.8 billion yuan for the same period a year ago. Its net profit stood at 1.2 billion yuan, an increase of 140.2 percent year-on-year from 500.8 million yuan in the same period a year earlier.
淮北治疗痔疮看什么科
The company said it will try its best to help prevent and control the spread of COVID-19 both at home and abroad with its quality POCT tests and services.
The company's sales in China jumped 7.2 percent from January to October, totaling 1.31 million units and showing the increasing importance of the Chinese market.
The company's net profits totaled 1.005 billion yuan (about 3 million), according to a statement the company filed with the Shanghai Stock Exchange.
The complete response for Brukinsa, or the absence of all detectable tumors, reached 59 percent among patients with relapsed or refractory MCL, and that for Calquence and Imbruvica were 40 percent and 21 percent respectively.